Halyard Health, Inc. (NYSE:HYH) was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating in a report issued on Saturday.

Several other equities research analysts have also weighed in on HYH. Stephens raised Halyard Health from an “equal weight” rating to an “overweight” rating in a research report on Thursday, August 3rd. Deutsche Bank AG raised their target price on Halyard Health from $35.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Zacks Investment Research lowered Halyard Health from a “buy” rating to a “hold” rating in a research report on Thursday, May 4th. Finally, TheStreet lowered Halyard Health from a “b-” rating to a “c” rating in a research report on Wednesday, May 3rd. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $42.25.

Shares of Halyard Health (NYSE:HYH) traded up 0.31% during midday trading on Friday, hitting $42.53. The stock had a trading volume of 251,460 shares. The firm has a 50 day moving average price of $40.53 and a 200 day moving average price of $38.98. The stock has a market cap of $1.99 billion, a PE ratio of 40.89 and a beta of 1.78. Halyard Health has a one year low of $31.59 and a one year high of $43.78.

Halyard Health (NYSE:HYH) last posted its quarterly earnings results on Wednesday, August 2nd. The medical instruments supplier reported $0.51 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.14. The company had revenue of $399.20 million for the quarter, compared to analyst estimates of $399.16 million. Halyard Health had a return on equity of 8.29% and a net margin of 3.06%. Halyard Health’s revenue for the quarter was down .2% compared to the same quarter last year. During the same quarter last year, the company earned $0.45 EPS. On average, equities analysts forecast that Halyard Health will post $1.98 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Halyard Health, Inc. (HYH) Stock Rating Upgraded by BidaskClub” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/08/19/halyard-health-inc-hyh-stock-rating-upgraded-by-bidaskclub.html.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Meadow Creek Investment Management LLC increased its position in Halyard Health by 1.1% in the first quarter. Meadow Creek Investment Management LLC now owns 2,660 shares of the medical instruments supplier’s stock worth $101,000 after buying an additional 28 shares in the last quarter. Glen Harbor Capital Management LLC increased its position in shares of Halyard Health by 1.1% in the first quarter. Glen Harbor Capital Management LLC now owns 3,230 shares of the medical instruments supplier’s stock valued at $123,000 after buying an additional 34 shares during the period. Patten Group Inc. increased its position in shares of Halyard Health by 0.4% in the first quarter. Patten Group Inc. now owns 19,629 shares of the medical instruments supplier’s stock valued at $769,000 after buying an additional 75 shares during the period. Amalgamated Bank increased its position in shares of Halyard Health by 1.2% in the second quarter. Amalgamated Bank now owns 6,655 shares of the medical instruments supplier’s stock valued at $261,000 after buying an additional 82 shares during the period. Finally, Somerset Trust Co increased its position in shares of Halyard Health by 0.7% in the second quarter. Somerset Trust Co now owns 12,618 shares of the medical instruments supplier’s stock valued at $495,000 after buying an additional 90 shares during the period. Hedge funds and other institutional investors own 90.32% of the company’s stock.

Halyard Health Company Profile

Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.

Receive News & Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.